Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
View Patent ↗The present invention provides compositions and methods of use thereof to prevent and/or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and/or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.
1. A method of preventing or treating pathogenic infection comprising administering a therapeutically effective amount of compositions comprising a tyrosine kinase inhibitor as set forth below to a patient in need thereof for preventing or treating infection caused by an array of pathogens:
2. The method of claim 1 , wherein said tyrosine kinase inhibitors are Ab 1- or Src-family tyrosine kinase inhibitors.
3. The method of claim 1 , wherein said pathogenic infection is caused by viral pathogens.
4. The method of claim 3 , wherein said viral pathogens are selected from the group consisting of Adenoviridae, Arenaviridae, Astroviridae, Bacteriophages, Baculoviridae, Bunyaviridae, Caliciviridae, Coronaviridae, Delta virus, Filoviridae, Flaviviridae, Geminiviridae, Hepadnaviridae, Herpesviridae, Nodaviridae, Orthomyxoviridae, Papovaviridae, Paramyxoviridae, Parvoviridae, Phycodnaviridae, Picornaviridae, Poxyiridae, Reoviridae, Retroviridae, Rhabdoviridae, Tobamoviridae, and Togaviridae, Poxviruses including Vaccinia and variola viruses, polyoma viruses including JC and BK viruses, Herpes viruses including Herpes Simplex virus, Epstein Barr virus, and Gamma Herpes virus, cytomegalovirus (CMV), and human immunodeficiency viruses (HIV-1).
5. The method of claim 3 , wherein said pathogenic infection is caused by poxvirus.
6. The method of claim 5 , wherein said pathogenic infection is caused by vaccinia viruses.
7. The method of claim 3 , wherein pathogenic infection is caused by Herpes viruses including Herpes Simplex virus, Epstein Barr virus, and Gamma Herpes virus.
8. The method of claim 1 , wherein said kinase inhibitor is
9. The method of claim 1 , wherein said pathogenic infection is an acute infection.
10. The method of claim 9 , wherein said acute infection is treated for less than three weeks.